Provided is a method for preparing 60% or more cis-di(C4-C20)alkyl cyclohexane-1,4-dicarboxylate which exhibits superior plasticizing property for PVC resin. Instead of a phthalate- or terephthalate-based aromatic ester derivative, 60% or more cis-dimethyl cyclohexane-1,4-dicarboxylate is used as a starting material. The 60% or more cis-dimethyl cyclohexane-1,4-dicarboxylate is subjected to transesterification with (C4-C20) primary alcohol to prepare 60% or more cis-di(C4-C20)alkyl cyclohexane-1,4-dicarboxylate. Methanol produced as a byproduct during the transesterification is removed and some of the primary alcohol, which is evaporated, is recycled. Thus prepared 60% or more cis-di(C4-C20)alkyl cyclohexane-1,4-dicarboxylate exhibits superior plasticizer characteristics, including good plasticizing efficiency for PVC resin, high absorption rate, good product transparency after gelling, less bleeding toward the surface upon long-term use, and the like.

Hanwha Chemical Corporation

Method of preparing of 60% or more CIS-DI(C4-C20)alkyl cyclohexane-1,4-dicarboxylate

A process for inhibiting platelet aggregation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN IS PHENYL OR CYCLOHEXANE AND X and Y can be the same or different and are hydrogen, fluoro, chloro, bromo, alkyl of from 1 to 8 carbon atoms, inclusive or alkoxy of from 1 to 8 carbon atoms inclusive, and the pharmacologically acceptable salts thereof to in vivo and in vitro platelet systems. In vitro systems include whole blood as kept in blood banks, whole blood as used in heart-lung machines and platelet-rich concentrates. In vivo systems include human or animal bodies. The process provides a means for treating hemorrhage due to thrombocytopenia which in turn is caused by irradiation cancer chemotherapy or immunosuppressants as well as hemophilia due to cogenital defects.

The Upjohn Company

Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds

A process for inhibiting platelet aggregation by the addition of a member selected from the group consisting of a compound of the formula: ##SPC1##Wherein is cyclohexane or phenyl; Y is hydrogen, halogen, --CF.sub.3, --OH, lower alkyl of 1 to 8 carbon atoms, lower alkoxy of 1 to 8 carbon atoms, --CN, --NH.sub.2, --SH, or --S-lower alkyl of 1 to 8 carbon atoms; and R is hydrogen, lower alkyl of 1 to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, to in vivo and in vitro platelet systems. In vitro systems include whole blood as kept in blood banks, whole blood as used in heart-lung machines, and platelet-rich concentrates. In vivo systems include human or animal bodies. The process provides a means for treating hemorrhage due to thrombocytopenia which in turn is caused by irradiation, cancer chemotherapy, or immunosuppressants as well as hemophilia due to congenital defects.

Process for inhibiting platelet aggregation

A process for inhibiting platelet aggregation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## wherein is cyclohexane or phenyl; Y is hydrogen, halogen --CF.sub.3, --OH, lower alkyl of 1 to 8 carbon atoms, lower alkoxy of 1 to 8 carbon atoms, --CN, --NH.sub.2. --SH, or --S-lower alkyl of 1 to 8 carbon atoms; R is hydrogen, lower alkyl of 1 to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, to in vivo and in vitro platelet systems. In vitro systems include whole blood as kept in blood banks, whole blood as used in heart-lung machines, and platelet-rich concentrates. In vivo systems include human or animal bodies. The process provides a means for treating hemorrhage due to thrombocytopenia which in turn is caused by irradiation, cancer chemotherapy, or immunosuppressants as well as hemophilia due to cogenital defects.

cyclohexane/hemorragia

Method of preparing of 60% or more CIS-DI(C4-C20)alkyl cyclohexane-1,4-dicarboxylate

Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds

Process for inhibiting platelet aggregation

Process for treating elevated platelet adhesiveness

O mais completo banco de dados de ervas medicinais apoiado pela ciência